Evotec Wins Research Grant to Advance H3 Receptor Antagonist Programme into the Clinic
The histamine H3 receptor is a drug target of high interest because of evidence that blocking this receptor in the brain can improve cognition, alertness and attention. H3 receptor antagonists therefore have the potential to become an important new class of therapy in a number of CNS indications, including excessive fatigue associated with conditions such as multiple sclerosis.
Dr Werner Lanthaler, Chief Executive Officer of Evotec commented: “We are happy that the Neu2 consortium has chosen to support our H3 receptor antagonist programme for further development within the BioPharma initiative. By driving these novel drug candidates from identification through to the first clinical steps, we can optimally capture the commercial value of this programme.”
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.